▲ S&P 500 +---% | ▲ Stock Advisor +---% Join The Motley Fool

Accessibility Log In Help

Daily Stock Gainers Daily Stock Losers Most Active Stocks

Daily Stock Gainers Daily Stock Losers Most Active Stocks

Keith Speights

TMFFishBiz

Keith Speights is a contributing Motley Fool Healthcare Analyst covering publicly traded companies across pharmaceuticals, biotechnology, medical devices, and marijuana. Prior to The Motley Fool, Speights was CEO of Constant Care Technology, a healthcare technology company; vice president of American HealthTech, a healthcare software company; and a director of operations for Blue Cross Blue Shield of Mississippi, a health insurer. He holds a B.S. in Industrial Engineering from Mississippi State University.

Recent Articles by Keith Speights

Test tubes with arrow

Sep 5, 2018 by Keith Speights

3 Monster Biotech Stocks in the Making

They're relatively small now, but these biotechs could be monster-sized winners over the long run.

$10 bills

Sep 5, 2018 by Keith Speights

3 Top Stocks Under $10

These low-priced stocks could generate high returns.

Marijuana leaf with money in background

Sep 4, 2018 by Keith Speights

Why Tilray, Inc. Shares Soared Today

Momentum for the marijuana stock continued as investors look ahead to the opening of Canada's recreational cannabis market and the potential for more big partnerships in the industry.

Marijuana buds, cigarettes, and Canadian maple leaf

Sep 2, 2018 by Keith Speights

Is Emerald Health Therapeutics Inc a Buy?

This Canadian marijuana stock has big opportunities -- but big risks, too.

Trump in meeting

Sep 2, 2018 by Keith Speights

Why the Trump Administration's Plot to Derail Marijuana Momentum Will Flop Bigly

Marijuana stock investors shouldn't worry about the federal government's secret plans to whack weed before it grows too much support.

Businessman touching networking technology icons

Sep 2, 2018 by Keith Speights

If I Could Buy Only 1 Stock, This Would Be It

This small company appears to be poised to dramatically disrupt a fast-growing market.

Question mark made of stacks of money

Sep 2, 2018 by Keith Speights

Is GW Pharmaceuticals PLC a Buy?

It's the biggest marijuana-focused biotech on the market. But will GW deliver for investors over the long run?

Marijuana plants on stacks of coins

Sep 2, 2018 by Keith Speights

Marijuana Stocks Canopy Growth, Cronos Group, and Tilray Could Easily Double -- If Not for This 1 Catch

These marijuana stocks are on a roll. And the roll would be much bigger except for this one huge obstacle.

Test tube and question mark

Sep 2, 2018 by Keith Speights

Better Buy: Amgen Inc. vs. Gilead Sciences, Inc.

Which stock wins in a one-on-one matchup between these two big biotechs?

Businessman looking at falling line chart

Aug 30, 2018 by Keith Speights

Why Cronos Group Shares Are Plunging Today

A critical report from a noted short-seller causes the marijuana stock to give up a lot of its recent gains.

FDA

Aug 30, 2018 by Keith Speights

Why Insys Therapeutics, Inc. Stock Skyrocketed Today

An FDA Fast Track designation appears to be making short-sellers of this biotech stock very nervous.

Yield with coins

Aug 30, 2018 by Keith Speights

3 High-Yield Healthcare Dividend Stocks Still Worth Buying

It's not too late to jump aboard these high-yield winners.

Marijuan leaf in front of globe

Aug 29, 2018 by Keith Speights

Why Cronos Group Inc. Stock Is Jumping Again Today

A deal to enter the Latin American market generated investor enthusiasm for the Canadian marijuana stock.

Marijuana leaf on top of $100 bill

Aug 29, 2018 by Keith Speights

Why Tilray Inc. Is Skyrocketing Today

A positive Q2 update sends the Canadian marijuana stock even higher.

Scientists and monitor

Aug 29, 2018 by Keith Speights

Is Celgene Corporation a Buy?

Risks? Celgene has plenty of them. But the big biotech also looks like a bargain with tremendous growth prospects.

Marijuana plants on stacks of coins

Aug 29, 2018 by Keith Speights

The Only 3 Numbers in Tilray's Q2 Earnings That Really Matter

Hint: They won't be found on the marijuana grower's top and bottom lines.

Businessman with we are hiring card

Aug 28, 2018 by Keith Speights

Johnson & Johnson Is Hiring -- and It's Ginormous News for Geron

A new job posted by the healthcare giant hints that good news could be on the way for Geron.

Mini human figures pushing green jigsaw pieces

Aug 28, 2018 by Keith Speights

Which Marijuana Partner Will Diageo Pick? Here Are 3 Top Candidates

Three Canadian cannabis producers that should definitely be on Diageo's short list.

Sell buy hold signs

Aug 28, 2018 by Keith Speights

UnitedHealth Group Stock Just Hit an All-Time High: Buy, Sell, or Hold?

Can the biggest health insurer keep racking up big gains?

Marijuana leaf with money in background

Aug 27, 2018 by Keith Speights

Why Marijuana Stocks Aphria, Cronos Group, and Tilray Are Surging Again Today

A deal with Diageo just might be on the way for one of these cannabis producers.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services